Sign In
Buy SLGL
$71.50
-2.23 (-3.02%)
At Close: Jun 03, 2026
Sol-Gel Technologies Ltd. (SLGL) Reports Q1 Loss, Lags Revenue Estimates
10:10am, Thursday, 28'th May 2026
Sol-Gel Technologies Ltd. (SLGL) came out with a quarterly loss of $1.31 per share versus the Zacks Consensus Estimate of a loss of $1.84.
Sol-Gel Reports First Quarter 2026 Financial Results and Provides Corporate Updates
08:00am, Thursday, 28'th May 2026
Sol-Gel received a Notice of Allowance for a method-of-use patent extending intellectual property protection for topical patidegib (SGT-610) until 2044 Sol-Gel completed an oversubscribed underwritten
Sol-Gel Technologies Ltd. Announces Pricing of Oversubscribed Underwritten Offering
09:38pm, Monday, 23'rd Mar 2026
NESS ZIONA, Israel, March 23, 2026 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (the “Company”) (NASDAQ: SLGL) today announced the pricing of an underwritten offering of 459,112 ordinary shares (
Sol-Gel Technologies Ltd. (SLGL) Reports Q4 Loss, Misses Revenue Estimates
03:01pm, Thursday, 19'th Mar 2026
Sol-Gel Technologies Ltd. (SLGL) came out with a quarterly loss of $1.07 per share versus the Zacks Consensus Estimate of $0.39.
Sol-Gel Files Annual Report on Form 20-F for the Year Ended December 31, 2025
08:53am, Thursday, 19'th Mar 2026
NESS ZIONA, Israel, March 19, 2026 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), announced today that it has filed its annual report on Form 20-F for the fiscal year ended December 3
Financial Survey: Assembly Biosciences (NASDAQ:ASMB) and Sol-Gel Technologies (NASDAQ:SLGL)
04:39am, Tuesday, 20'th Jan 2026
Sol-Gel Technologies (NASDAQ: SLGL - Get Free Report) and Assembly Biosciences (NASDAQ: ASMB - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will comp
Opaleye Management Inc. Buys 22,497 Shares of Sol-Gel Technologies (NASDAQ:SLGL) Stock
05:10am, Friday, 02'nd Jan 2026
Sol-Gel Technologies Ltd. (NASDAQ: SLGL - Get Free Report) major shareholder Opaleye Management Inc. acquired 22,497 shares of the stock in a transaction on Wednesday, December 31st. The stock was bou
Opaleye Management Inc. Acquires 8,638 Shares of Sol-Gel Technologies (NASDAQ:SLGL) Stock
05:10am, Friday, 02'nd Jan 2026
Sol-Gel Technologies Ltd. (NASDAQ: SLGL - Get Free Report) major shareholder Opaleye Management Inc. acquired 8,638 shares of Sol-Gel Technologies stock in a transaction dated Monday, December 29th. T
Opaleye Management Inc. Acquires 35,169 Shares of Sol-Gel Technologies (NASDAQ:SLGL) Stock
04:27am, Friday, 02'nd Jan 2026
Sol-Gel Technologies Ltd. (NASDAQ: SLGL - Get Free Report) major shareholder Opaleye Management Inc. acquired 35,169 shares of Sol-Gel Technologies stock in a transaction that occurred on Tuesday, Dec
Why Is Small Cap Sol-Gel Tech Stock Falling Today?
01:47pm, Wednesday, 17'th Dec 2025
Sol-Gel Technologies ends development of SGT-210 in Darier disease after Phase 1b data show no efficacy versus vehicle.
Sol-Gel Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
07:30am, Thursday, 20'th Nov 2025
Sol-Gel intends to pursue high-frequency BCC as an additional indication for its lead drug candidate SGT-610, which, if approved, could at least double the drug's commercial potential In September 202
Sol-Gel Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
07:00am, Friday, 15'th Aug 2025
Patient enrollment for our ongoing Phase-3 clinical trial of SGT-610 for Gorlin Syndrome has been completed; top-line results are expected in the fourth quarter of 2026 Phase-1b proof-of-concept clini
Sol-Gel Reports First Quarter 2025 Results
07:15am, Friday, 23'rd May 2025
NESS ZIONA, Israel, May 23, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company, today announced financial results for the first quarter ended Mar
Sol-Gel Announces Reverse Share Split
07:00am, Thursday, 01'st May 2025
NESS ZIONA, Israel, May 01, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (the “Company”) (NASDAQ: SLGL), a clinical-stage dermatology company, today announced a reverse share split (the “R
Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S.
08:40am, Thursday, 17'th Apr 2025
Sol-Gel to receive $16 million during 2025 Cash runway is expected to extend into the first quarter of 2027; Company expects to have sufficient cash to complete its Phase III clinical trial SGT-610 Ph
